
Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 04, 2020, titled "Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India".
Filed with NSE ·

Cadila Healthcare Limited has informed the Exchange regarding a press release dated December 04, 2020, titled "Zydus receives approval from DCGI to commence Phase III clinical trials with Pegylated Interferon alpha-2b in India".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences